At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CR crane
Pre-Mkt 10-06 07:17:03 EDT
209.61
+1.41
+0.68%
High213.36Low205.94Vol505.49K
Open209.16D1 Closing208.20Amplitude3.56%
Mkt Cap12.07BTradable Cap11.98BTotal Shares57.60M
T/O106.60MT/O Rate0.88%Tradable Shares57.15M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

CR Holdings Subsidiary Chosun Refractories Wins KRW 35 Billion POSCO Supply Deal
TIPRANKS  ·  12:13
CR Holdings Subsidiary Chosun Refractories Wins KRW 35 Billion POSCO Supply Deal
Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors
GlobeNewswire  ·  10-05 19:30
Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors
New Zealand King Salmon Shareholder CR Assets to Sell Nearly 10% Stake to Oregon Group, PHT
MT Newswires Live  ·  10-01
New Zealand King Salmon Shareholder CR Assets to Sell Nearly 10% Stake to Oregon Group, PHT
Crane Lead Independent Director James Tullis to Retire After 2027 Annual Meeting
Reuters  ·  09-30
Crane Lead Independent Director James Tullis to Retire After 2027 Annual Meeting
Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory AL Amyloidosis
GlobeNewswire  ·  09-29
Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory AL Amyloidosis
CR Double-Crane Pharma Unit's Propranolol Injection Passes Generic Drug Evaluation
MT Newswires Live  ·  09-24
CR Double-Crane Pharma Unit's Propranolol Injection Passes Generic Drug Evaluation
CR Construction Wins HK$1.5 Billion Public Housing Contract in Hong Kong
TIPRANKS  ·  09-18
CR Construction Wins HK$1.5 Billion Public Housing Contract in Hong Kong
Crane Price Target Maintained with a $245.00/Share by DA Davidson
Dow Jones  ·  09-15
Crane Price Target Maintained with a $245.00/Share by DA Davidson
Analysts Offer Insights on Industrial Goods Companies: Argan (AGX) and Crane Company (CR)
TIPRANKS  ·  09-15
Analysts Offer Insights on Industrial Goods Companies: Argan (AGX) and Crane Company (CR)
Trillium - Deal Valued at About $240 Mln
THOMSON REUTERS  ·  09-14
Trillium - Deal Valued at About $240 Mln
Crane Agrees to Buy Trillium Flow Technologies’ U.S. Pump Business for $240 Million
Reuters  ·  09-14
Crane Agrees to Buy Trillium Flow Technologies’ U.S. Pump Business for $240 Million
Crane Company Announces Agreement to Acquire U.S. Water Pump Business from First Reserve-Backed Trillium Flow Technologies
THOMSON REUTERS  ·  09-14
Crane Company Announces Agreement to Acquire U.S. Water Pump Business from First Reserve-Backed Trillium Flow Technologies
Crane Company - Deal Valued at $240 Mln, Representing 14.6X Estimated 2026 Adj Ebitda
THOMSON REUTERS  ·  09-14
Crane Company - Deal Valued at $240 Mln, Representing 14.6X Estimated 2026 Adj Ebitda
CR Double-Crane Pharma Gets China Registration for Brain Surgery Irrigation Solution
MT Newswires Live  ·  09-09
CR Double-Crane Pharma Gets China Registration for Brain Surgery Irrigation Solution
E KOCREF CR-REIT Receives Clean Audit Opinions and Posts Stable Earnings
TIPRANKS  ·  09-08
E KOCREF CR-REIT Receives Clean Audit Opinions and Posts Stable Earnings
Crane Director James L. L. Tullis Disposes of 400 Shares Worth $82,150
Reuters  ·  09-03
Crane Director James L. L. Tullis Disposes of 400 Shares Worth $82,150
CR Sanjiu Gets Registration Approval for 1 Billion Yuan Bonds
MT Newswires Live  ·  09-02
CR Sanjiu Gets Registration Approval for 1 Billion Yuan Bonds
Crane : Deutsche Bank Cuts Target Price to $240 from $248
THOMSON REUTERS  ·  09-01
Crane : Deutsche Bank Cuts Target Price to $240 from $248
CR Double-Crane Pharma Gets Registration Certificate for Oxcarbazepine Tablets
MT Newswires Live  ·  09-01
CR Double-Crane Pharma Gets Registration Certificate for Oxcarbazepine Tablets
U.S. Research Roundup-Autodesk, Hubspot, Oracle
Reuters  ·  09-01
U.S. Research Roundup-Autodesk, Hubspot, Oracle

Introduction

Company Name.
crane
Affiliated Markets:
NYSE
Listing Date:
--
Main Business:
Crane NXT, Co. focuses on payment and merchandising technologies. It indents to offer electronic equipment and associated software leveraging extensive, and proprietary core capabilities, including payment verification and authentication, as well as automation solutions, field service solutions, remote diagnostics, and productivity enhancing software solutions. The company is based in Stamford, Connecticut.
Issue price:
--